Vanda Pharmaceuticals (VNDA) said Monday that the US Food and Drug Administration has accepted the new drug application for Bysanti to potentially treat bipolar I disorder and schizophrenia, with a target decision date of Feb. 21, 2026.
The FDA has not identified any potential review issues at this time, Vanda said.
The company said the application is supported by data from studies in acute episodes of schizophrenia, a study in bipolar I disorder with manic or mixed episodes, and a relapse prevention study in schizophrenia.
Bysanti is currently being evaluated as a once-daily add-on treatment for major depressive disorder, with results expected in 2026, the biopharmaceutical company said.
Shares of Vanda Pharmaceuticals were down more than 2% in recent Monday trading.
Price: 4.47, Change: -0.10, Percent Change: -2.19
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.